JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis

Blood

Volumn 108, Issue 5, 2006, Pages 1652-1660

  Lacout, Catherine ^b   Pisani, Didier F ^b   Tulliez, Micheline ^b   Gachelin, Françoise Moreau ^b   Vainchenker, William ^b   Villeval, Jean Luc ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ANEMIA; ANIMAL MODEL; ARTICLE; FIBROSIS; GENE ACTIVITY; GENE EXPRESSION; GRANULOCYTOSIS; HEMATOPOIETIC CELL; IN VIVO STUDY; MEGALOCYTOSIS; MOUSE; MYELOFIBROSIS; NEUTROPHILIA; NONHUMAN; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; SPLENOMEGALY; STEM CELL; THROMBOCYTOPENIA; THROMBOCYTOSIS; AMINO ACID SUBSTITUTION; ANIMAL; BONE MARROW CELL; C57BL MOUSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

AMINO ACID SUBSTITUTION; ANIMALS; BONE MARROW CELLS; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RETROVIRIDAE;

EID: 33745721197     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-002030     Document Type: Article

References (27)

1. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41:1-5.
2. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera [Letter]. N Engl J Med. 1974;290:1382.
3. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology. 2003:200-224.
4. Taksin AL, Couedic JP, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125-139.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
9. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005;11:546-554.
10. Dorsch M, Zheng G, Yowe D, et al. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease. Blood. 2002;100:2046-2055.
11. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol. 1988;62:1120-1124.
12. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369-4383.
13. Cabane C, Englaro W, Yeow K, Ragno M, Derijard B. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38alpha pathway. Am J Physiol Cell Physiol. 2003;284:C658-C666.
14. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature. 1988;331:277-280.
15. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409.
16. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
17. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-1338.
18. Schindler CW. Series introduction: JAK-STAT signaling in human disease. J Clin Invest. 2002;109:1133-1137.
19. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251-27261.
20. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
21. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-18967.
22. Villeval JL, Metcalf D, Johnson GR. Fatal polycythemia induced in mice by dysregulated erythropoietin production by hematopoietic cells. Leukemia. 1992;6:107-115.
23. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:8520-8530.
24. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100:1123-1132.
25. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495-3503.
26. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006;107:4139-4141.
27. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281. (Prepublished February 14, 2006, as DOI 10.1182/blood-2005- 12-4824.)